American Century Companies’s GSK GSK Stock Holding History

American Century Companies’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$96.4M	Buy	1,838,479 +222,471	+14%	+$11.8M	0.04%	519
2026 Q1	$89.2M	Buy	1,616,008 +384,300	+31%	+$20.8M	0.05%	483
2025 Q4	$60.4M	Buy	1,231,708 +147,119	+14%	+$6.86M	0.03%	642
2025 Q3	$46.8M	Buy	1,084,589 +162,861	+18%	+$6.36M	0.02%	737
2025 Q2	$35.4M	Buy	921,728 +216,892	+31%	+$8.29M	0.02%	817
2025 Q1	$27.3M	Buy	704,836 +51,971	+8%	+$1.9M	0.02%	881
2024 Q4	$22.1M	Buy	652,865 +58,056	+10%	+$2.09M	0.01%	994
2024 Q3	$24.3M	Buy	594,809 +50,730	+9%	+$2.08M	0.01%	938
2024 Q2	$20.9M	Buy	544,079 +161,448	+42%	+$6.79M	0.01%	940
2024 Q1	$16.4M	Buy	382,631 +45,561	+14%	+$1.88M	0.01%	1004
2023 Q4	$12.5M	Buy	337,070 +79,907	+31%	+$2.87M	0.01%	1058
2023 Q3	$9.32M	Sell	257,163 -154,791	-38%	-$5.49M	0.01%	1087
2023 Q2	$14.7M	Buy	411,954 +50,123	+14%	+$1.8M	0.01%	894
2023 Q1	$12.9M	Buy	361,831 +46,144	+15%	+$1.61M	0.01%	919
2022 Q4	$11.1M	Buy	315,687 +76,139	+32%	+$2.54M	0.01%	936
2022 Q3	$7.05M	Buy	239,548 +96,556	+68%	+$3.66M	0.01%	1004
2022 Q2	$7.78M	Buy	142,992 +8,621	+6%	+$476K	0.01%	989
2022 Q1	$7.32M	Buy	134,371 +49,628	+59%	+$2.7M	0.01%	1002
2021 Q4	$4.67M	Buy	84,743 +4,648	+6%	+$242K	﹤0.01%	1080
2021 Q3	$3.83M	Buy	80,095 +17,226	+27%	+$865K	﹤0.01%	1098
2021 Q2	$3.13M	Buy	62,869 +26,055	+71%	+$1.25M	﹤0.01%	1097
2021 Q1	$1.64M	Buy	36,814 +5,023	+16%	+$228K	﹤0.01%	1230
2020 Q4	$1.46M	Sell	31,791 -2,243,063	-99%	-$103M	﹤0.01%	1142
2020 Q3	$107M	Buy	2,274,854 +558,440	+33%	+$28M	0.09%	241
2020 Q2	$87.5M	Buy	1,716,414 +1,658,536	+2,866%	+$85.1M	0.08%	256
2020 Q1	$2.74M	Buy	57,878 +46,016	+388%	+$2.45M	﹤0.01%	804
2019 Q4	$697K	Buy	+11,862	New	+$660K	﹤0.01%	1133

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

American Century Companies's GSK Position: Q2 2026 in Review

American Century Companies increased its GSK (GSK) stake by 14% in Q2 2026, buying an estimated $11.8M and bringing the position to 1,838,479 shares worth $96.4M. The position accounts for 0.04% of the portfolio, ranked #519.

American Century Companies first reported a position in GSK in Q4 2019 and has held it in 27 quarters since. The position peaked at $107M in Q3 2020. 1,039 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

American Century Companies held 1,838,479 shares of GSK worth $96.4M as of Q2 2026.
American Century Companies bought 222,471 GSK shares in Q2 2026, an estimated $11.8M.
GSK made up 0.04% of American Century Companies's portfolio in Q2 2026, its #519 holding.
American Century Companies first reported a position in GSK in Q4 2019 and has held it in 27 quarters since.
American Century Companies's GSK position peaked at $107M in Q3 2020.
1,039 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.